Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2026-01-26 @ 5:27 AM
Study NCT ID:
NCT05011058
Status:
TERMINATED
Last Update Posted:
2025-07-28
First Post:
2021-08-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Sponsor:
Viracta Therapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Epstein-Barr Virus Associated Lymphoma | View |
| None | EBV-Positive DLBCL, NOS | View |
| None | EBV-Related Non-Hodgkin Lymphoma | View |
| None | EBV Related PTCL, NOS | View |
| None | EBV-Related Hodgkin Lymphoma | View |
| None | EBV-Related PTLD | View |
| None | EBV-Related Lymphoproliferative Disorder | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Epstein-Barr virus (EBV) | View |
| None | EBV-positive lymphomas | View |
| None | EBV-positive T-cell lymphoma | View |
| None | EBV-positive Hodgkin lymphoma | View |
| None | EBV-positive diffuse large B-cell lymphoma (DLBCL) | View |
| None | EBV-positive extranodal natural killer/T-cell lymphoma | View |
| None | EBV-positive peripheral T-cell lymphoma (PTCL) | View |
| None | EBV-positive post-transplant lymphoproliferative disorders | View |